Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kingworld Medicines GroupHKSE:01110 -2.06%43 EV-to-FCF is 5.90 as of Aug. 13, 2026, which is 6% above its 10-year median of 5.54. GuruFocus rates HKSE:01110 with a GF Score™ of 43/100 and a GF Value™ of HK$0.50 (Fairly Valued). The stock has 5 warning signs investors should review. Among 407 Healthcare Providers & Services companies, Kingworld Medicines Group ranks better than 86.49% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kingworld Medicines Group's Enterprise Value is HK$551 Mil.
Kingworld Medicines Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$93 Mil. Therefore, Kingworld Medicines Group's EV-to-FCF for today is 5.90.
The historical rank and industry rank for Kingworld Medicines Group's EV-to-FCF or its related term are showing as below:
HKSE:01110'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.66 Med: 5.54 Max: 28.63
Current: 5.81
During the past 13 years, the highest EV-to-FCF of Kingworld Medicines Group was 28.63. The lowest was -30.66. And the median was 5.54.
HKSE:01110's EV-to-FCF is ranked better than 86.49% of 407
companies
in the Healthcare Providers & Services industry
Industry Median: 18.7
vs HKSE:01110: 5.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kingworld Medicines Group (HKSE:01110) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kingworld Medicines Group's PE Ratio (TTM) for today is calculated as:
Kingworld Medicines Group's share price for today is HK$0.475.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kingworld Medicines Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kingworld Medicines Group EV-to-FCF Related Terms
Kingworld Medicines Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group EV-to-FCF Competitor Comparison
For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kingworld Medicines Group EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kingworld Medicines Group's EV-to-FCF falls into.
Kingworld Medicines Group's current Enterprise Value is HK$551 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kingworld Medicines Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group (HKSE:01110) has a EV-to-FCF of 5.90 as of Aug. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kingworld Medicines Group and its competitors. This is near median its historical median of 5.54. According to the industry distribution chart, Kingworld Medicines Group ranks #55 out of 407 companies in the Healthcare Providers & Services industry, placing it in the top 13.5%.
Is Kingworld Medicines Group's EV-to-FCF too high?
Kingworld Medicines Group's current EV-to-FCF of 5.90 is near median its 10-year median of 5.54. The Healthcare Providers & Services industry median EV-to-FCF is 18.70. Kingworld Medicines Group's value of 5.90 is 68.4% below this industry median. Based on the distribution chart, Kingworld Medicines Group ranks #55 out of 407 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Kingworld Medicines Group has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kingworld Medicines Group's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Kingworld Medicines Group ranks #55 out of 407 companies for EV-to-FCF. This places Kingworld Medicines Group in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.70. Kingworld Medicines Group's value of 5.90 is 68.4% below this benchmark. While the company's 10-year median is 5.54 vs. the industry median of 18.70, Kingworld Medicines Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kingworld Medicines Group's current EV-to-FCF of 5.90 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kingworld Medicines Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kingworld Medicines Group's current EV-to-FCF is 5.90, which is near median its own 10-year median of 5.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kingworld Medicines Group stock overvalued right now?
Based on GuruFocus' analysis, Kingworld Medicines Group (HKSE:01110) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.50, compared to a current price of HK$0.48 — trading 5% below its estimated fair value. The current EV-to-FCF is 5.90, which is near median its 10-year median of 5.54 and 68.4% below the Healthcare Providers & Services industry median of 18.70. Kingworld Medicines Group's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kingworld Medicines Group (HKSE:01110), the current EV-to-FCF is 5.90 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kingworld Medicines Group (HKSE:01110) Overvalued in 2026?
Based on GuruFocus' analysis, Kingworld Medicines Group stock appears to be undervalued.
The current stock price of HK$0.48 is trading 5% below its estimated GF Value™ of HK$0.50.
GuruFocus considers Kingworld Medicines Group to be Fairly Valued.
Key valuation signals for HKSE:01110:
EV-to-FCF: 5.90 (near median its 10-year median of 5.54)
GF Value™: HK$0.50 vs. price of HK$0.48 (5% below fair value)
Industry Position: 68.4% below the Healthcare Providers & Services median (#55 of 407)
No single metric tells the full story. See the HKSE:01110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kingworld Medicines Group Ltd is engaged in the Distribution of pharmaceutical and healthcare products, such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from the Distribution sales of the pharmaceutical and healthcare products segment.
43GF Score
Get the complete analysis for HKSE:01110
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01110 has been successfully added to your 
